Avelumab
- Generic Name
- Avelumab
- Brand Names
- Bavencio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1537032-82-8
- Unique Ingredient Identifier
- KXG2PJ551I
- Background
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year, it was also granted approval by EMA and Health Canada, respectively. It is used in the treatment of Merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.
- Indication
Avelumab is indicated for the treatment of adults with metastatic Merkel cell carcinoma (MCC). In the US, it is also used in patients 12 years and older.
It is also indicated as the maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma (UC), which has not progressed with first-line platinum-containing chemotherapy. In the US, avelumab is also indicated to treat locally advanced or metastatic UC with disease progression during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Avelumab is indicated, in combination with axitinib, for the first-line treatment of advanced renal cell carcinoma (RCC).
- Associated Conditions
- Advanced Renal Cell Carcinoma, Metastatic Urothelial Cancer, Locally advanced Urothelial Carcinoma, Metastatic Merkel Cell Carcinoma (MCC)
- Associated Therapies
- First Line Chemotherapy, Maintenance therapy
Anti-PD-L1 and SAbR for Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 5
- Registration Number
- NCT03312114
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Avelumab With Chemoradiation in Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-10-03
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 37
- Registration Number
- NCT03299660
- Locations
- 🇦🇺
Box Hill Hospital, Box hill, Victoria, Australia
🇦🇺Cabrini Hospital, Malvern, Victoria, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Universitair Ziekenhuis Brussel
- Target Recruit Count
- 52
- Registration Number
- NCT03291314
- Locations
- 🇧🇪
UZ Brussel, Brussel, Belgium
Avelumab in G2-3 NET
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 17
- Registration Number
- NCT03278379
- Locations
- 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Avelumab in G3 NEC
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 10
- Registration Number
- NCT03278405
- Locations
- 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Adjuvant Avelumab in Merkel Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 101
- Registration Number
- NCT03271372
- Locations
- 🇺🇸
University of California Irvine Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸University of Colorado Cancer Center University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-09-01
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 54
- Registration Number
- NCT03270176
- Locations
- 🇨🇦
British Columbia Cancer Agency, Vancouver, British Columbia, Canada
🇷🇴Institutul Oncologic "Prof. Dr. Ion Chiricuţă" Cluj Napoca, Cluj-Napoca, Romania
🇷🇴Centrul de Oncologie, S.C. Centrul de Oncologie Sf. Nectarie S.R.L, Oncologie Medicala, Craiova, Romania
Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma
- Conditions
- Interventions
- First Posted Date
- 2017-08-30
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 9
- Registration Number
- NCT03267836
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
- Conditions
- Interventions
- First Posted Date
- 2017-08-24
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Transgene
- Target Recruit Count
- 150
- Registration Number
- NCT03260023
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇫🇷I.C.O. Paul Papin, Angers, France
🇫🇷CHU Besançon, Besançon, France
A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Effector Therapeutics
- Target Recruit Count
- 56
- Registration Number
- NCT03258398
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.